Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor

Executive Summary

Pfizer's efforts to sustain growth for Lipitor in the face of forthcoming competition from generic versions of Merck's Zocor will focus on educating payers about atorvastatin's positive impact on overall healthcare costs relative to simvastatin, CEO Hank McKinnell said Jan. 4

You may also be interested in...



After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

New Scripts May Be Juiced By Plan Switches Accompanying Part D – IMS

The number of new prescriptions reported since the implementation of Medicare Part D could be artificially inflated due to patients changing plans

Related Content

UsernamePublicRestriction

Register

PS046747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel